In this episode of WTR Healthcare Happenings, Robert Sassoon, Managing Director of Healthcare Equity Research at Water Tower Research, joins host Tim Gerdeman to discuss his newly published initiation of coverage on Circular Genomics, a privately held molecular diagnostics company developing blood-based tests using circular RNA (circRNA) biomarkers.
Robert Sassoon explains the science behind circRNA and discusses the company’s Alzheimer’s research published in Nature Medicine in July, including its locked 34-circRNA signature and its potential to complement established biomarkers such as pTau217. The conversation explores why predicting disease progression could be particularly valuable for Alzheimer’s clinical trials, where identifying patients most likely to decline during a study may improve trial efficiency and outcomes.
The discussion also covers Circular Genomics’ staged commercialization strategy, beginning with its CircPATH research-use platform and biopharma partnerships before moving toward clinical diagnostics. Robert Sassoon outlines the key milestones investors should watch, from initial contracts and independent validation to financing, clinical development, and the longer-term commercial opportunity.
For additional content, visit www.watertowerresearch.com.
